CTOs on the Move

Accolade Inc

www.accoladeinc.com

 
Conventional approaches aren't getting the job done so we've taken a whole new approach to helping individuals make more informed, confident choices. We've built a company for the sole purpose of engaging and delighting your employees and supporting them with every health benefits or healthcare question they have. We've proven that by giving employees and their families a great service and helping them get the right care that we can create more satisfied and committed employees and lower healthcare costs for employers. We've aligned our people, processes and technology to do the hard work of simplifying healthcare. We partner with large, ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Eden Spine

Eden Spine is a Lake Mary, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ascend Healthcare

Ascend Healthcare is a residential treatment facility for teens struggling with mental health and addiction issues. They provide evidence-based therapies, experiential therapies, and a unique clinical approach to help their clients. Their focus on fami...

Cooley Dickinson Hospital

Cooley Dickinson Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Cooley Dickinson Hospital is based in Northampton, MA. You can find more information on Cooley Dickinson Hospital at www.cooley-dickinson.org

Healthcare Resource Network

Healthcare Resource Network is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.